Detailed Information

Cited 1 time in webofscience Cited 1 time in scopus
Metadata Downloads

Prognosis and Sensitivity of Adjuvant Chemotherapy in Mucinous Colorectal Adenocarcinoma without Distant Metastasis

Authors
Bong, Jun-WooGim, Jeong-AnJu, YeonukCheong, ChinockLee, Sun-IlOh, Sang-CheulMin, Byung-WookKang, Sanghee
Issue Date
Mar-2022
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Keywords
colorectal cancer; mucinous adenocarcinoma; chemotherapy resistance; TCGA; consensus molecular subtype
Citation
Cancers, v.14, no.5
Indexed
SCIE
SCOPUS
Journal Title
Cancers
Volume
14
Number
5
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/55493
DOI
10.3390/cancers14051297
Abstract
Simple Summary Although chemotherapy plays an essential role in improving the survival rate of colorectal cancer, it is administered regardless of the histological classification of colorectal cancer. Mucinous adenocarcinoma is the second most common histological subtype of colorectal cancer after adenocarcinoma, accounting for 6-21% of cases. While mucinous adenocarcinoma has several poor clinical prognostic factors, controversy persists regarding its poor survival rate. The results of this study, based on analysis of the National Health Insurance database, demonstrated that mucinous adenocarcinoma has a poor survival rate related to chemoresistance. This occurs owing to the molecular properties of mucinous adenocarcinoma associated with inflammation and epithelial-mesenchymal transition (EMT). EMT, a chemoresistance-inducing pathway, increases with mucinous adenocarcinoma progression. Further studies on the development of personalized chemotherapy focusing on the molecular properties of mucinous adenocarcinoma will help improve the survival rate of patients with colorectal cancer. Abstract In colorectal cancer, whereas mucinous adenocarcinoma (MAC) has several poor clinical prognostic factors compared to adenocarcinoma (AC), the prognosis of MAC remains controversial. We evaluated the prognosis of MAC without distant metastasis and the effects of adjuvant chemotherapy using health insurance registry data managed by South Korea. Patients with colorectal cancer between January 2014 and December 2016 were included (AC, 22,050 [96.8%]; MAC, 729 [3.2%]). We observed no difference in overall survival (OS) between AC and MAC in stages I and II. However, MAC showed a worse OS than AC in stage III disease, especially in patients administered chemotherapy (p < 0.001). These findings persisted after propensity score matching of clinical characteristics between AC and MAC. In addition, transcriptome analysis of The Cancer Genome Atlas (TCGA) data showed increased chemoresistance-associated pathways in MAC compared to AC. In consensus molecular subtypes (CMS) classification, unlike in AC, CMSs 1, 3, and 4 comprised most of MAC and the proportions of CMSs 3 and 4 increased with stage progression. These results suggest clues to overcome resistance to chemotherapy and develop targeted treatments in MAC.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
5. Others > Medical Science Research Management Center > 1. Journal Articles
2. Clinical Science > Department of Colon and Rectal Surgery > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Oh, Sang Cheul photo

Oh, Sang Cheul
Guro Hospital (Department of Medical Oncology and Hematology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE